MOH

Current Thesis

Managed-care "trough-year" rotation. After Molina detonated on its Q4 2025 print (~Feb 2026) — adjusted loss of -$2.75/sh and a 2026 adjusted-EPS guide slashed to ≥$5.00 vs ~$13.71 consensus, stock -28% — the Q1 2026 report (late April) was the first stabilization signal: adjusted EPS $2.35, consolidated MCR 91.1%, FY26 guide reaffirmed, stock +9–17%. The trade here is mean-reversion off a washed-out base as Medicaid rates slowly catch up to cost trend. But the easy relief leg already ran: MOH is +58% off the $121.06 low and now stalling near $191 (2026-06-04). This is a MATURING recovery, not an accelerating narrative, and there is no fresh catalyst inside 30 days — Q2 print is ~late July.

Bull Case

• Q1 2026 beat + reaffirm (late Apr 2026): adj EPS $2.35, consolidated MCR 91.1%, FY26 reaffirmed at ~$42B premium revenue / ≥$5.00 adj EPS / ≥$1.90 GAAP — management says medical cost trend ran "modestly favorable" to plan.
• Acuity shift fading: the 250bps Medicaid acuity mismatch that wrecked 2025 is "largely diminished and not expected to recur"; 2026 built on a 5% cost-trend assumption — if real trend lands below that, the ≥$5.00 guide is sandbagged.
• Trough-year normalization: sector consensus calls 2026 the trough for Medicaid margins, underfunded ~300–400bps. Rate filings catch up over 12–24 mo (Centene citing mid-4% Medicaid net rate increases, CMS +5.06% MA rate for 2026) → 2027–28 earnings power well above the $5 trough.
• Valuation reset: down ~38% from the $311.53 52-wk high; UBS lifted PT to $202 (2026-05-22), sell-side range $128–$202 with most at Hold — a low bar that's easy to clear if trend behaves.
• Self-help: exiting the unprofitable MA-PD product for 2027 ($93M Q1 impairment) removes a loss-making drag.

Bear Case

• Medicaid MLR still hot: Q1 2026 Medicaid MLR 93.5% (Centene 93.1%) — well above the high-80s that signals healthy margin. Cost control is unproven beyond one quarter.
• ACA subsidy cliff: enhanced premium tax credits expired end-2025; Marketplace effectuated enrollment projected to fall from 22.3M (2025) to ~17.5M (2026, -25%), premiums up a median 18%. Molina's Marketplace book shrinks and adverse-selects into 2027.
• Enrollment bleed: Molina Medicaid membership -5.8% since H.R.1 (worst of the Big Five), pressuring revenue (Q1 premium rev -4% YoY to ~$10.2B).
• Optical valuation: GAAP P/E ~54x is impairment-distorted; even on ≥$5.00 adj EPS that's ~38x forward on trough earnings — no margin of safety if the trough extends.
• Credibility tax: management slashed guidance hard in Feb and drew investor/legal scrutiny on cost assumptions; any Q2 wobble re-prices the credibility discount.

Setup & Price Structure

• Price 2026-06-04: ~$191.55, intraday $188.43–$192.28; market cap ~$10B.
• 52-wk range $121.06–$311.53 — stock sits mid-range, ~38% below the high, +58% off the low.
• Structure = post-capitulation recovery: Feb gap-down to the lows, Q1-beat relief gap higher (late Apr), now consolidating/stalling ~$190 with no follow-through. The momentum impulse has cooled.
• Not stretched, not breaking out — a chop zone. For a momentum book this is no-man's-land: the recovery thesis is intact but there's no accelerating leg to buy and no clean breakout trigger. Post-Q1 base support ~$165–170.

Catalyst Calendar (next 30 days)

• No earnings inside 30 days — Q2 2026 print is ~late July 2026 (binary on whether MCR/cost-trend control holds; avoid fresh entry ≤3 trading days prior).
• 2026-06 to 07: state Medicaid rate-filing / 2027 ACA Marketplace rate-filing headlines (median +18% proposed) — incremental, not a step-change.
• ~July 2026: peer prints (UNH, CNC, ELV) front-run MOH and set sector tone; a CNC/UNH beat or miss moves MOH sympathetically before its own report.
• Net: catalyst_date = null for the 30-day window. Nothing scheduled to force a re-rate before late July.

What Would Change Our Mind

• Bullish re-engage: weekly close and hold above the post-relief highs (~$205–210, clearing the UBS $202 PT) on a peer-cluster sector breakout → upgrade from probe; OR a Q2 print with Medicaid MLR stepping toward ~92% confirming trend control.
• Thesis broken / exit: weekly close below $170 (gives back the post-Q1 relief gap); OR Q2 2026 Medicaid MCR re-expands >93.5% / FY26 adj-EPS guide cut below $5.00 — either signals the acuity/trend problem is recurring, not transient. That's the "trough wasn't the trough" tell and ends the trade.
• Hard macro override: a confirmed extension of enhanced ACA premium tax credits would flip the Marketplace overhang to a tailwind — re-rate everything higher.

Correlation Notes

• Tightly coupled to the managed-care complex: CNC, ELV, HUM, CVS, UNH. MOH and CNC are the highest-beta Medicaid-pure names — they move together on rate-adequacy and cost-trend headlines; UNH's MCR (83.9% Q1) is the sector bellwether.
• Policy-driven, not AI-driven: zero correlation to the AI/semis complex; drivers are CMS rate notices, Medicaid redetermination data, and ACA subsidy legislation. This is a defensive/value rotation vehicle, the opposite end of the book from momentum-tech.
• Sympathy risk: a single-name blowup at any Big Five insurer (à la the 2025 UNH cost shock) drags the whole group regardless of MOH's own numbers — concentration in one managed-care name is effectively a sector bet.